Cellectis Presents Preclinical APOC3 Editing Data at ESGCT 2026
Cellectis presented preclinical data highlighting APOC3 editing and triglyceride reduction with.HEAL-101 at ESGCT 2026.
Related stories
Federated Hermes Reports Quarterly Results
Federated Hermes reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Gaming and Leisure Properties Reports Quarterly Results
Gaming and Leisure Properties reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Invesco Mortgage Capital Reports Quarterly Results
Invesco Mortgage Capital reported results for the quarter ended September 30; no figures were provided.
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
AIA Group's Third-Quarter New Business Value Falls 5%
M impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Stocks in Australia Hit 7-week High
ASX200 increased to 8937.00 Index Points, the highest since September 2026. Over the past 4 weeks, Australia Stock Market Index (AU200) gained 1.64%, and in the last 12 months, it
L impact | EQUITY | Oct 29, 2026, 11:21 PM UTC
Schneider National Reports Quarterly Results for Period Ended September 30
Schneider National reported results for the quarter ended September 30. The supplied summary does not include the results figures.
M impact | EQUITY | Oct 29, 2026, 11:20 PM UTC